文献速递神经肿瘤

立体定向放射外科治疗Koos IV级前庭神经鞘瘤:一项多中心研究

Stereotactic radiosurgery for Koos grade IV vestibular schwannoma: a multi-institutional study.
PubMed 文献 · J Neurosurg · 2022-06-03

该回顾性多中心研究纳入10个中心的627例接受初次单次立体定向放射外科(SRS)治疗的Koos IV级前庭神经鞘瘤患者,中位随访38个月时肿瘤控制率为94.1%,5年和10年可用听力保留率分别为65%和44.6%,面神经功能恶化发生率为3.0%,作者建议处方剂量<13 Gy以降低面瘫风险。

要点

  • Koos IV级前庭神经鞘瘤接受初次单次SRS后,94.1%的患者获得肿瘤控制。
  • 5年和10年可用听力保留率分别为65%和44.6%。
  • 面神经功能恶化发生率为3.0%,与边缘剂量≥13 Gy和早期肿瘤增大相关。

核心结论

  • SRS是获得Koos IV级前庭神经鞘瘤肿瘤控制的安全有效方法,尤其适用于有手术合并症而不宜切除的患者。
  • 为降低SRS后面瘫发生率,作者推荐处方剂量<13 Gy。

研究设计与样本

  • 回顾性多中心研究,纳入10个中心接受初次单次SRS治疗的Koos IV级前庭神经鞘瘤患者。
  • 纳入标准为出现非危及生命或致残症状且至少有12个月临床和神经影像随访。
  • 共纳入627例患者(344例女性,中位年龄54岁,IQR 22岁)。

主要发现

  • 中位肿瘤体积8.7 cm³(IQR 5),中位处方剂量12 Gy(IQR 1),中位影像随访38个月(IQR 54)。
  • SRS前可用听力、面神经无力(House-Brackmann分级>I)和三叉神经病变分别见于205例(33%)、48例(7.7%)和203例(32.4%)患者。
  • 末次随访时肿瘤控制率为94.1%,早期肿瘤增大发生于67例(10.7%)患者并与末次随访时肿瘤控制丧失相关(p=0.001)。
  • 5年和10年随访时可用听力保留率分别为65%和44.6%,Gardner-Robertson分级>1(p=0.003)和耳蜗剂量≥4 Gy(p=0.02)是听力丧失的危险因素。
  • 末次随访时面神经功能恶化发生于19例(3.0%)患者,与边缘剂量≥13 Gy(p=0.03)和早期肿瘤增大(p=0.04)相关;SRS后33例患者发生需分流治疗的脑积水;92例患者发生放射不良反应,其中34例和18例分别接受药物和手术治疗。

临床怎么用

  • 作者推荐处方剂量<13 Gy以降低SRS后面瘫发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Though stereotactic radiosurgery (SRS) is an established safe treatment for small- and medium-sized vestibular schwannomas (VSs), its role in the management of Koos grade IV VS is still unclear. In this retrospective multicenter study, the authors evaluated tumor control and the patient outcomes of primary, single-session SRS treatment for Koos grade IV VS. METHODS: This study included patients treated with primary, single-session SRS for Koos grade IV VS at 10 participating centers. Only those patients presenting with non-life-threatening or incapacitating symptoms and at least 12 months of clinical and neuroimaging follow-up were eligible for inclusion. Relevant data were collected, and the Kaplan-Meier method was used to perform time-dependent analysis for post-SRS tumor control, hearing preservation, and facial nerve function preservation. Univariate and multivariate analyses were performed for outcome measures using Cox regression analysis. RESULTS: Six hundred twenty-seven patients (344 females, median patient age 54 [IQR 22] years) treated with primary SRS were included in this study. The median tumor volume was 8.7 (IQR 5) cm3. Before SRS, serviceable hearing, facial nerve weakness (House-Brackmann grade > I), and trigeminal neuropathy were present in 205 (33%), 48 (7.7%), and 203 (32.4%) patients, respectively. The median prescription dose was 12 (IQR 1) Gy. At a median radiological follow-up of 38 (IQR 54) months, tumor control was achieved in 94.1% of patients. Early tumor expansion occurred in 67 (10.7%) patients and was associated with a loss of tumor control at the last follow-up (p = 0.001). Serviceable hearing preservation rates at the 5- and 10-year follow-ups were 65% and 44.6%, respectively. Gardner-Robertson class > 1 (p = 0.003) and cochlear dose ≥ 4 Gy (p = 0.02) were risk factors for hearing loss. Facial nerve function deterioration occurred in 19 (3.0%) patients at the last follow-up and was associated with margin doses ≥ 13 Gy (p = 0.03) and early tumor expansion (p = 0.04). Post-SRS, 33 patients developed hydrocephalus requiring shunting. Adverse radiation effects occurred in 92 patients and were managed medically or surgically in 34 and 18 cases, respectively. CONCLUSIONS: SRS is a safe and effective method of obtaining tumor control in patients with Koos grade IV VS presenting with non-life-threatening or debilitating symptoms, especially those with surgical comorbidities that contraindicate resection. To decrease the incidence of post-SRS facial palsy, a prescription dose < 13 Gy is recommended.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Pikis S, Mantziaris G, Kormath Anand R, et al. Stereotactic radiosurgery for Koos grade IV vestibular schwannoma: a multi-institutional study. J Neurosurg. 2022. PMID: 36303474. doi:10.3171/2022.4.JNS22203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。